TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28267071

Group type: EXPERIMENTAL
Intervention: Vibration anesthesia (DentalVibe device)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham (device off)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Comparison of sham vs intervention
Number of subjects: 25
Study: 26843724

Group type: EXPERIMENTAL
Intervention: 100 ml of instant coffee divided into three portions right after removing the nasogastric tube, first postoperative day
Number of subjects: 61

Group type: COMPARATOR
Intervention: 100 ml of tea
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 100 ml of instant coffee
Number of subjects: 61
Study: 24075659

Group type: EXPERIMENTAL
Intervention: Moderate force (50-g force applied bilaterally to the first premolars for 1, 4, 8, or 12 weeks)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Severe force (300-g force applied bilaterally to the first premolars for 1, 4, 8, or 12 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (3 subjects)
Number of subjects: 27
Study: 21804130

Group type: EXPERIMENTAL
Intervention: torcetrapib plus atorvastatin
Number of subjects: 6661

Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 6661
Study: 19509505

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 6

Group type: COMPARATOR
Intervention: Midazolam (75 microg kg(‐1))
Number of subjects: 6
Study: 16460338

Group type: EXPERIMENTAL
Intervention: Ropivacaine alone (0.75% ropivacaine, 1.8 ml)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ropivacaine + epinephrine (1.8 ml)
Number of subjects: 32
Study: 15488338

Group type: EXPERIMENTAL
Intervention: Preparation stage of change
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Precontemplators
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Depressive symptom severity and history of recurrent depressive episodes
Number of subjects: 322
Study: 11789710

Group type: EXPERIMENTAL
Intervention: Dental health counselling
Number of subjects: 268

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 268
Study: 9032501

Group type: EXPERIMENTAL
Intervention: 3 month rehabilitation programme including drug treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control period of drug treatment only
Number of subjects: 0
Study: 8320490

Group type: EXPERIMENTAL
Intervention: Intravenous deferoxamine (DFO) at 180 mg/kg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Intravenous deferoxamine (DFO) at 150 mg/kg/day for 3 months
Number of subjects: 6
Study: 3560265

Group type: EXPERIMENTAL
Intervention: Hematocrit maintained near 30% (n = 12)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hematocrit maintained near 40% (n = 13)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (30% and 40% HCT)
Number of subjects: 25
Study: 31221106

Group type: EXPERIMENTAL
Intervention: FLASH intervention (community-based health-promoting school intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLASH intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control schools (four control schools)
Number of subjects: 0
Study: 29272301

Group type: EXPERIMENTAL
Intervention: Amplitude training (30 minutes/day, five days/week for six weeks)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group (stretch and relaxation exercises at equal intensity)
Number of subjects: 38
Study: 26004980

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment adherence at six months assessment
Number of subjects: 1154

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment adherence at twelve months assessment
Number of subjects: 1154
Study: 23698210

Group type: EXPERIMENTAL
Intervention: Nanohydroxyapatite group (20 patients)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (20 patients)
Number of subjects: 40
Study: 21945448

Group type: EXPERIMENTAL
Intervention: Calcium lactate pentahydrate (CLP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium linear polyphosphate (LPP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CLP + LPP
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Xanthan gum (XG)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium tripolyphosphate (STP)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium pyrophosphate tetrabasic (PP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Pure orange juice (C-)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcium-modified juice (C+)
Number of subjects: 15
Study: 19793095

Group type: EXPERIMENTAL
Intervention: Sertaconazole 2% cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Miconazole 2% cream
Number of subjects: 100
Study: 17893603

Group type: EXPERIMENTAL
Intervention: Group C: basiliximab, TAC (0.05 mg/kg twice daily) plus MMF (1 g twice daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Group A: Thymoglobulin, CsA (4 mg/kg twice daily) plus azathioprine (1.5 mg/kg once daily)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group B: basiliximab, CsA (2 mg/kg twice daily) plus MMF (1 g twice daily)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Group A
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group B
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Group C
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study: 15089813

Group type: COMPARATOR
Intervention: Quinidine (600 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11903524

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9972405

Group type: EXPERIMENTAL
Intervention: Tenoxicam (40 mg intravenously)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8067552

Group type: EXPERIMENTAL
Intervention: ondansetron 0.15 mg/kg intravenously
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: metoclopramide 0.25 mg/kg intravenously
Number of subjects: 90

Group type: COMPARATOR
Intervention: normal saline 0.3 mL/kg (Control)
Number of subjects: 90
Study: 3054622

Group type: EXPERIMENTAL
Intervention: Maprotiline (116.75 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Chlorimipramine (116.25 mg/day)
Number of subjects: 40
Study: 31155764

Group type: EXPERIMENTAL
Intervention: Standard care with prophylactic protocol and monitoring (enzyme declogging kits administered every 7 days for 4 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Standard care with prophylactic protocol and monitoring (enzyme declogging kits)
Number of subjects: 49
Study: 28609319

Group type: EXPERIMENTAL
Intervention: methylprednisolone 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: methylprednisolone 40 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide 20 mg
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide 40 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 62
Study: 28739492

Group type: EXPERIMENTAL
Intervention: Citalopram (30±5.8 mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Quetiapine (94.0±40.4 mg/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Olanzapine (5.2±1.6 mg/d)
Number of subjects: 75
Study: 25688740

Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 569

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine
Number of subjects: 569
Study: 24038103

Group type: EXPERIMENTAL
Intervention: Active treatment (specifics not provided)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Tumor grading, tumor size, lymph node involvement
Number of subjects: 354

Group type: COMPARATOR
Intervention: No active treatment (implied control group)
Number of subjects: 354
Study: 21925353

Group type: EXPERIMENTAL
Intervention: Kinematic scores using miniature sensors (3-dimensional gyroscopes and accelerometers)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Regular outcome scores (SST, Disabilities of the Arm, Shoulder and Hand, American Shoulder and Elbow Surgeons, Constant)
Number of subjects: 34
Study: 18954621

Group type: EXPERIMENTAL
Intervention: Autologous fibrin sealant applied along the staple lines on one side
Number of subjects: 25

Group type: COMPARATOR
Intervention: No additional measure taken on the other side (Control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Autologous fibrin sealant
Number of subjects: 25
Study: 16565560

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) treatment, subcutaneously injected once a day for 10 days at a low dose.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Non-G-CSF control group.
Number of subjects: 46
Study: 12603186

Group type: EXPERIMENTAL
Intervention: Fluticasone 100 microg daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fluticasone 1000 microg daily
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fluticasone 2000 microg daily
Number of subjects: 3
Study: 10926069

Group type: EXPERIMENTAL
Intervention: 1 mg morphine intra‐articularly (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 150 microg clonidine intra‐articularly (group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1 mg morphine + 150 microg clonidine intra‐articularly (group 3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline intra‐articularly (group 4)
Number of subjects: 60
Study: 8724108

Group type: EXPERIMENTAL
Intervention: LPL-D9N mutation carriers (cases)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-carriers (cases)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LPL-D9N mutation carriers (controls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-carriers (controls)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPL-D9N mutation carriers (cases and controls with BMI > 26.0 kg/m2)
Number of subjects: 0
Study: 1570800

Group type: EXPERIMENTAL
Intervention: High-fat (HF) diet
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: High-carbohydrate (HC) diet
Number of subjects: 21
Study: 2416412

Group type: EXPERIMENTAL
Intervention: Nasogastric tube insertion under direct laryngoscopy using Magill forceps
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nasogastric tube insertion blindly during the surgical procedure
Number of subjects: 80
Study: 30010228

Group type: EXPERIMENTAL
Intervention: Stricter parental rules
Number of subjects: 6300

Group type: EXPERIMENTAL
Intervention: Higher initial levels of sensation seeking
Number of subjects: 6300
Study: 29298184

Group type: EXPERIMENTAL
Intervention: Sucrose administration
Number of subjects: 114

Group type: COMPARATOR
Intervention: Breastfeeding
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Both groups (sucrose and breastfeeding)
Number of subjects: 114
Study: 27100085

Group type: EXPERIMENTAL
Intervention: Jump Squat (JS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olympic Push Press (OPP)
Number of subjects: 0
Study: 24140033

Group type: EXPERIMENTAL
Intervention: Prolutex (25 mg subcutaneously daily)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Crinone (90 mg 8% gel daily)
Number of subjects: 683
Study: 22987458

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBOT) at 153 kPa (1.5 ATA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham air at 116 kPa (1.15 ATA)
Number of subjects: 60
Study: 20594090

Group type: EXPERIMENTAL
Intervention: Qigong or Tai Chi interventions
Number of subjects: 77
Study: 17414047

Group type: EXPERIMENTAL
Intervention: Valacyclovir (1,000 mg/d for 5 days) plus prednisolone (VP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo plus prednisolone (PP)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Valacyclovir plus prednisolone (VP) in cases of complete or severe palsy
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo plus prednisolone (PP) in cases of complete or severe palsy
Number of subjects: 221
Study: 15184614

Group type: EXPERIMENTAL
Intervention: Iyengar yoga class along with home practice
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Aerobic exercise class using a stationary bicycle along with home exercise
Number of subjects: 69

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 69
Study: 11434406

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum extract WS5572 (300 mg t.i.d.)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Hypericum perforatum extract WS5572
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hypericum perforatum extract WS5572 and Placebo
Number of subjects: 72
Study: 9164914

Group type: EXPERIMENTAL
Intervention: 60 degrees head-up tilt for 5 minutes
Number of subjects: 26
Study: 8435016

Group type: EXPERIMENTAL
Intervention: Budesonide 800 micrograms twice a day via a spacer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms twice a day via a spacer and facemask
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3300427

Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 20

Group type: COMPARATOR
Intervention: halothane
Number of subjects: 20
Study: 29717032

Group type: EXPERIMENTAL
Intervention: Tanezumab (pooled all treatment doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite outcomes (including WOMAC pain and rescue medication use)
Number of subjects: 0
Study: 27578313

Group type: EXPERIMENTAL
Intervention: MMA with preemptive analgesia
Number of subjects: 75

Group type: COMPARATOR
Intervention: MMA without preemptive analgesia
Number of subjects: 75
Study: 24876261

Group type: EXPERIMENTAL
Intervention: Intravenous tissue‐type plasminogen activator (tPA) followed by endovascular therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous tissue‐type plasminogen activator (tPA) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular therapy with routine use of general anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular therapy without routine use of general anesthesia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Embolectomy for IMS III subjects
Number of subjects: 0
Study: 23865696

Group type: EXPERIMENTAL
Intervention: Gonadotropin initiation 3 weeks after GnRHa administration (Group A)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Gonadotropin initiation 2 weeks after GnRHa administration (Group B)
Number of subjects: 85
Study: 20528810

Group type: EXPERIMENTAL
Intervention: Pre-cessation nicotine patches and/or gum for 2 weeks prior to quit day
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 1100
Study: 18837607

Group type: EXPERIMENTAL
Intervention: Guided self-help treatments
Number of subjects: 75
Study: 16652426

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronic acid (HA) injections (20 mg/ml, 2 ml) administered once weekly for 3 weeks
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (saline) injections administered once weekly for 3 weeks
Number of subjects: 106
Study: 12796754

Group type: EXPERIMENTAL
Intervention: enalapril
Number of subjects: 468

Group type: COMPARATOR
Intervention: nisoldipine
Number of subjects: 468
Study: 10750292

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) after laparoscopic hysterectomy (LH) and/or bilateral salpingo‐oophorectomy (BSO)
Number of subjects: 286

Group type: COMPARATOR
Intervention: No estrogen replacement therapy (control group)
Number of subjects: 286
Study: 8943183

Group type: COMPARATOR
Intervention: Transabdominal approach (group I)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Transthoracic transdiaphragmatic approach (group II)
Number of subjects: 44
Study: 1424415

Group type: EXPERIMENTAL
Intervention: Single-dose sotalol (320 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Repeated sotalol administration
Number of subjects: 10
Study: 6147154

Group type: EXPERIMENTAL
Intervention: Vecuronium 73 microgram kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancuronium 99 microgram kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Vecuronium and Pancuronium (1.6 ED95)
Number of subjects: 60
Study: 30842540

Group type: EXPERIMENTAL
Intervention: UFP + O3
Number of subjects: 18

Group type: COMPARATOR
Intervention: UFP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Air
Number of subjects: 18
Study: 29921562

Group type: EXPERIMENTAL
Intervention: Internet-based and mobile-based stress management interventions (iSMIs)
Number of subjects: 791

Group type: COMPARATOR
Intervention: Waitlist control group (WLC)
Number of subjects: 791
Study: 27176461

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 0.5 mg/kg
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Bapineuzumab 1.0 mg/kg
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1012

Group type: EXPERIMENTAL
Intervention: Bapineuzumab (both doses)
Number of subjects: 1012
Study: 26040789

Group type: EXPERIMENTAL
Intervention: Phototherapy (PHO)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Muscle-stretching, aerobic, and facial exercises (EXT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phototherapy plus exercise interventions (PHO + EXT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (PHO, EXT, PHO + EXT, Control)
Number of subjects: 60
Study: 21824124

Group type: EXPERIMENTAL
Intervention: Laser dermabrasion followed by hydrocortisone 17-butyrate cream and narrowband UVB treatment
Number of subjects: 18

Group type: COMPARATOR
Intervention: Topical steroids and UVB alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Laser-treated side
Number of subjects: 18

Group type: COMPARATOR
Intervention: UVB + steroids alone group
Number of subjects: 18
Study: 20216113

Group type: EXPERIMENTAL
Intervention: Computer-assisted dosing (MAP-BE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CONTR)
Number of subjects: 40
Study: 18823199

Group type: EXPERIMENTAL
Intervention: Temporal integration of target and mask stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spatial properties of the target and mask
Number of subjects: 0
Study: 15695140

Group type: EXPERIMENTAL
Intervention: Intravenous monteplase followed by PCI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Direct PCI
Number of subjects: 0
Study: 11838852

Group type: EXPERIMENTAL
Intervention: Topical ice therapy, oral prednisone 30 mg PO tapered to 0 over 6 days, and colchicine 0.6 mg/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group received the same regimen without ice therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Topical ice therapy
Number of subjects: 19
Study: 10354080

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) ointment 0.005% (g/g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study: 7588895

Group type: EXPERIMENTAL
Intervention: Collagen plug implantation after coronary stenting
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Collagen plug implantation after PTCA
Number of subjects: 309

Group type: COMPARATOR
Intervention: Conventional haemostasis after coronary stenting
Number of subjects: 309

Group type: COMPARATOR
Intervention: Conventional haemostasis after PTCA
Number of subjects: 309
Study: 2144866

Group type: EXPERIMENTAL
Intervention: Recombinant vaccine, 10 micrograms in 1 ml intramuscularly
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Plasma-derived vaccine, 2 micrograms in 0.1 ml intradermally
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Recombinant vaccine, 1 microgram in 0.1 ml intradermally
Number of subjects: 153
Study: 6137116

Group type: EXPERIMENTAL
Intervention: Combination of cimetidine and pirenzepine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Cimetidine or pirenzepine alone
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cimetidine and ranitidine as prophylaxis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: H2-receptor antagonists and pirenzepine
Number of subjects: 100
Study: 31249180

Group type: EXPERIMENTAL
Intervention: Modified Bass with lift the lip
Number of subjects: 40

Group type: COMPARATOR
Intervention: Modified Bass without lift the lip
Number of subjects: 40

Group type: COMPARATOR
Intervention: Horizontal technique with lift the lip
Number of subjects: 40

Group type: COMPARATOR
Intervention: Horizontal technique without lift the lip
Number of subjects: 40
Study: 28699090

Group type: EXPERIMENTAL
Intervention: Physical activity interventions (specific details not provided)
Number of subjects: 172
Study: 26545456

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (indoor treadmill)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (indoor progressive-muscle relaxation/stretching)
Number of subjects: 40
Study: 24513624

Group type: EXPERIMENTAL
Intervention: 15TT (15-second all-out sprint)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 90TT (90-second all-out sprint)
Number of subjects: 9

Group type: COMPARATOR
Intervention: SPTT (self-paced time trial)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 15TT
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 90TT
Number of subjects: 9
Study: 22183192

Group type: EXPERIMENTAL
Intervention: PHAST PACES intervention (60 to 70 hours of instruction)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: PHAST PACES intervention (1 year follow-up)
Number of subjects: 268
Study: 21149774

Group type: EXPERIMENTAL
Intervention: Longitudinal analyses using change probability with total and pattern deviation
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Cross-sectional analyses using glaucoma hemifield test, corrected pattern standard deviation, and mean deviation
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Pattern deviation analyses
Number of subjects: 1570

Group type: EXPERIMENTAL
Intervention: Longitudinal and cross-sectional analyses
Number of subjects: 1570